Login | Register

ESC 2025 Highlights: An Update for Clinical Practice

Categories: ESC
Wishlist Share
Share Course
Page Link
Share On Social Media

About Course

Welcome to this educational update on the key highlights from the European Society of Cardiology (ESC) Congress 2025. This course is designed to provide clinicians with a concise overview of the most impactful clinical trials and research presented, with a focus on translating new evidence into clinical practice. We will explore four major themes that emerged from this year’s congress: addressing neglected populations in cardiovascular medicine, advancing precision medicine in rare cardiomyopathies, navigating controversies in post-myocardial infarction (MI) management, and understanding the role of inflammation as a cardiovascular risk factor. Each module will delve into a key clinical trial, discuss its implications, and provide actionable insights for your daily practice.

Show More

Course Content

Module 1: Addressing Neglected Populations in Cardiovascular Medicine
Chagas disease, caused by the parasite Trypanosoma cruzi, represents a significant global health burden, particularly in Latin America where it is endemic. An estimated 6 to 7 million people worldwide are infected, with a substantial proportion developing chronic Chagas cardiomyopathy, a severe and often fatal form of heart disease. Despite its prevalence, Chagas cardiomyopathy has remained a neglected area of cardiovascular research, with limited evidence to guide optimal treatment strategies. Patients with Chagas-related heart failure have historically been underrepresented in major clinical trials, leading to uncertainty about the applicability of standard heart failure therapies in this unique population.

  • The PARACHUTE-HF Trial: A Landmark Study
    07:57

Module 2: Advancing Precision Medicine in Rare Cardiomyopathies
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive, and often fatal disease caused by the deposition of misfolded transthyretin (TTR) protein in the heart muscle. This deposition leads to restrictive cardiomyopathy, heart failure, and arrhythmias. Historically, ATTR-CM has been underdiagnosed and often mistaken for other forms of heart failure. However, with advancements in imaging and diagnostic techniques, there is a growing recognition of its prevalence and clinical significance. The management of ATTR-CM has been challenging, with limited therapeutic options available to halt or reverse the disease process.

Module 3: Navigating Controversies in Post-Myocardial Infarction Management
Beta-blockers have been a cornerstone of post-myocardial infarction (MI) management for decades. Numerous clinical trials have demonstrated their benefit in reducing mortality and recurrent ischemic events, particularly in patients with reduced left ventricular ejection fraction (LVEF). However, the role of beta-blockers in patients with preserved or mildly reduced LVEF has been a subject of ongoing debate. With advancements in reperfusion therapies and secondary prevention strategies, the incremental benefit of beta-blockers in this population has been questioned.

Module 4: Understanding Inflammation as a Cardiovascular Risk Factor
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. While traditional risk factors, such as hypertension, hyperlipidemia, and diabetes, are well-established drivers of CVD, a significant proportion of cardiovascular events occur in individuals without these so-called "Standard Modifiable Risk Factors" (SMuRFs). This has led to a growing interest in identifying novel risk factors that can help to better stratify patients and guide preventive strategies

Student Ratings & Reviews

No Review Yet
No Review Yet